Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | KDM5A | P29375 | 9/20 | 0.51 |
| ▸ | LTA4H | P09960 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374162 | 0.90 | MEN1 (0.61) | MEN1KMT2ATSHRKDM5ALTA4H | |
| SCHEMBL14430424 | 0.90 | MEN1 (0.71) | MEN1KMT2ATSHRKDM5ALTA4H | |
| SCHEMBL8375565 | 0.87 | KMT2A (0.57) | MEN1KMT2ATSHRKDM5ALTA4H | |
| SCHEMBL18499076 | 0.86 | KMT2A (0.65) | MEN1KMT2ATSHRKDM5ALTA4H | |
| SCHEMBL12168832 | 0.85 | KDM5A (0.69) | MEN1KMT2ATSHRKDM5ALTA4H | |
| SCHEMBL23016787 | 0.83 | KDM5A (0.69) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL22483458 | 0.83 | MEN1 (0.57) | MEN1KMT2ATSHRKDM5ALTA4H | |
| SCHEMBL4007439 | 0.83 | KDM5A (0.69) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL23016785 | 0.83 | KDM5A (0.69) | MEN1KMT2ATSHRKDM5AKDM4C | |
| SCHEMBL26629541 | 0.82 | MEN1 (0.79) | MEN1KMT2ATSHRKDM5ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| CN-101663284-A | Macrocyclic compounds as hcv ns3 protease inhibitors | NOVARTIS AG | 2010-03-03 | — | — | CN | disclosed |
| EP-2125757-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101665-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101665-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | MEN1 4723/4885KMT2A 3834/4885TSHR 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.